{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:35:40Z","timestamp":1771472140110,"version":"3.50.1"},"reference-count":8,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.2169\/internalmedicine.3675-19","type":"journal-article","created":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T22:03:29Z","timestamp":1570399409000},"page":"339-343","source":"Crossref","is-referenced-by-count":1,"title":["Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis"],"prefix":"10.2169","volume":"59","author":[{"given":"Nao","family":"Okamoto","sequence":"first","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuteru","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36: 2585-2594, 2015.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2: 113-122, 2014.","DOI":"10.1016\/j.jchf.2013.11.004"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135: 1357-1377, 2017.","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66: 2451-2466, 2015.","DOI":"10.1016\/j.jacc.2015.09.075"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Izumiya Y, Takashio S, Oda S, Yamashita Y, Tsujita K. Recent advances in diagnosis and treatment of cardiac amyloidosis. J Cardiol 71: 135-143, 2018.","DOI":"10.1016\/j.jjcc.2017.10.003"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133: 282-290, 2016.","DOI":"10.1161\/CIRCULATIONAHA.115.018852"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379: 11-21, 2018.","DOI":"10.1056\/NEJMoa1805689"},{"key":"8","unstructured":"8. The EPOCH Study Group. Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 66: 149-157, 2002."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/3\/59_3675-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T03:43:44Z","timestamp":1580528624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/3\/59_3675-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3675-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}